About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisory Board

Dan Marks

Board Observer

Dan Marks is a Principal on the Venture Team at RA Capital Management. Dan’s primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells.